6533b835fe1ef96bd129ebe4
RESEARCH PRODUCT
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study
Vito FrancoAlessandro PulsoniLuigi MarcheselliGiuseppina RicciutiEmilio IannittoStefano LuminariAlberto FragassoFrancesco MerliElisa MontechiarelloMassimo FedericoClaudio TripodoMarina CesarettiMarco PaulliCaterina StelitanoSalvatrice MancusoAngelo Michele Carellasubject
MaleCancer ResearchBiopsymedicine.medical_treatmentfirst lineKaplan-Meier EstimateSplenic marginal zone lymphoma; first line; rituximabPolyethylene GlycolGastroenterologyPolyethylene GlycolsrituximabBone MarrowPrednisonefirst line; rituximab; splenic marginal zone lymphomaCause of DeathAntineoplastic Combined Chemotherapy ProtocolsSplenic marginal zone lymphomaAged 80 and overHematologyMiddle AgedPrognosisCombined Modality TherapySplenic NeoplasmTreatment OutcomeItalyOncologyVincristineFemaleRituximabHumanmedicine.drugAdultmedicine.medical_specialtyVincristineLymphoma B-CellCyclophosphamidePrognosiSplenectomySplenic NeoplasmNeutropeniaImmunophenotypingfirst line; rituximab; Splenic marginal zone lymphoma; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marrow; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Immunophenotyping; Italy; Kaplan-Meier Estimate; Lymphoma B-Cell; Male; Middle Aged; Polyethylene Glycols; Prednisone; Prognosis; Rituximab; Splenic Neoplasms; Treatment Outcome; Vincristine; Hematology; Oncology; Cancer ResearchInternal medicinemedicineHumansSplenic marginal zone lymphomaCyclophosphamideAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industrySplenic NeoplasmsBiomarkermedicine.diseaseSurgeryDoxorubicinPrednisonebusinessBiomarkersdescription
Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%). Of the 15 deaths, two occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, four to secondary neoplasia, one to sepsis, one to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.
year | journal | country | edition | language |
---|---|---|---|---|
2015-01-01 |